Kogavant

Ticagrelor, the active ingredient in Kogavant, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of acute coronary syndrome and for secondary prevention of thrombotic events after myocardial infarction in adult patients. GNH USA supplies Kogavant as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kogavant (ticagrelor) is used in the antiplatelet therapy pathway for cardiovascular disease. - Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke in patients presenting with ACS. - ST-elevation myocardial infarction (STEMI): improves outcomes when added to standard care in STEMI patients. - Non‑ST-elevation myocardial infarction (NSTEMI): lowers recurrent ischemic events in NSTEMI management. - Unstable angina: decreases the incidence of further cardiac events in patients with unstable angina. - Secondary prevention after myocardial infarction: prevents recurrent thrombotic events in post‑MI patients.

Ticagrelor may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dyspnea: shortness of breath, often transient. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools without severe dehydration.

Serious or Rare Side Effects: - Major bleeding: life‑threatening hemorrhage requiring medical intervention. - Thrombotic thrombocytopenic purpura: rare hematologic disorder. - Severe allergic reactions: anaphylaxis or angioedema.

Before prescribing ticagrelor, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Assess bleeding risk: review history of hemorrhage, recent surgery, or anticoagulant use. - Monitor hepatic function: adjust use in patients with severe liver impairment. - Evaluate renal function: caution in severe renal dysfunction. - Avoid in patients with active pathological bleeding. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Ticagrelor interacts with several drug classes that can alter its antiplatelet efficacy or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Concurrent anticoagulants (e.g., warfarin, DOACs): heighten bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise concentrations. - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): monitor for myopathy. - Digoxin: increased serum levels may occur; monitor renal function.